Cancer Center Support Grant

描述（由申请人提供）：丹娜-法伯/哈佛癌症中心（DF/HCC）现已运营12年，是该国第一个联盟模式，NCI指定的综合癌症中心。该联盟由来自五家主要哈佛附属医院和两所哈佛健康科学学院的1，015名成员组成：贝斯以色列女执事医疗中心（BIDMC），布里格姆妇女医院（BWH），波士顿儿童医院（CHB），达纳法伯癌症研究所（DFCI），哈佛医学院（HMS），哈佛公共卫生学院（HSPH）和马萨诸塞州总医院（MGH）。 本提案中提出的进展需要总部大楼/合同委员会的领导、其综合资源，以及最重要的是其联合体结构。总体科学愿景是团结成员。该中心的研究是在跨越科学和机构边界的研究计划中进行的。此外，该中心还支持共享资源，致力于提高所有中心成员的科学效率。统一的临床研究基础设施使成员更容易在整个中心进行临床试验。科学进步的间接迹象是该中心的可持续发展投资组合的大幅增长，从1999年的2.33亿美元增加到2004年的4.06亿美元，再增加到2009年的6.23亿美元，以及授予超越组织边界的多项翻译赠款（例如，SPORE、SCORs、P01、U 01和SU 2C）。还有一系列假设驱动的早期阶段（试点，I，I-II）和概念验证试验，通过中心的开发和执行，每天在整个联盟中进行。

DESCRIPTION (provided by applicant): Now in its 12th year of operation, Dana-Farber/Harvard Cancer Center (DF/HCC) is the first consortium model, NCI-designated Comprehensive Cancer Center in the country. The consortium is comprised of 1,015 members from five principal Harvard-affiliated hospitals and two Harvard health science schools: Beth Israel Deaconess Medical Center (BIDMC), Brigham and Women's Hospital (BWH), Children's Hospital Boston (CHB), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Harvard School of Public Health (HSPH), and Massachusetts General Hospital (MGH). The progress presented in this proposal has required DF/HCC leadership, its combined resources, and, most importantly, its consortium structure. The overarching scientific vision is to unite the members. The research of the Center is carried out in Research Programs that cross both scientific and institutional boundaries. In addition, the Center supports Shared Resources dedicated to enhancing scientific efficiency available to all Center members. The unified clinical research infrastructure has made it easier for members to conduct clinical trials across the Center. Indirect indications of scientific progress are the substantial growth in the Center's gran portfolio, from $233 million in 1999 to $406 million in 2004, to $623 million in 2009, and the award of multiple translational grants that transcend organizational boundaries (e.g., SPOREs, SCORs, P01s, U01s, and SU2Cs). There is also an array of hypothesis-driven, Early Phase (pilot, I, I-II), and proof-of-concept trials, made possible through the development and execution of the Center, that are conducted daily across the consortium.